Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT Forward 2 empasiprubart IV monotherapy in AChR-antibody positive generalized myasthenia gravis
NL-OMON61358Phase 2Not yet recruiting
- Sponsor
- argenx
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of empasiprubart in myasthenia gravis (MG), sponsored by argenx. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
empasiprubart
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON61358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61358.